



GIST incidence

Third-line treatment GIST survival

Post-resection GIST TTT

Proportion of resectable GIST

Yearly background mortality

Imatinib treated GIST TTT

Sunitinib treated GIST TTT

0.0

0.5

1.0

1.5

2.0

**Third-line treatment GIST prevalence per 100,000 persons**